Anticancer role of dendritic cells (DC) in human and experimental cancers--a review.

Abstract

The bone marrow-derived dendritic cells (DL/LC) are antigen-presenting accessory cells functioning as part of the immune system. In addition, DC/LC in epithelial tissues may have the capacity to be involved in cellular interactions which may have regulatory functions. Such properties can also be noted when LC/DC interact with cancer cells in tumors. The present review summarizes reports which suggest that the outcome of a primary tumor in patients depends on the presence or absence of DC/LC in the tumor. The evidence showing that the presence of DC/LC in primary tumors indicates that a good prognosis may be reached are presented and discussed. Based on these observations and the ability of immunomodulators to enhance the activity of DC/LC and the ability of these cells to enter into tumors, it is suggested that the molecular basis of DC/LC activity against primary tumors cells should be investigated. It is possible that activation of DC/LC, thereby enhancing their ability to enter primary tumors, and the abrogation of the ability of DC/LC-resistant tumors to destroy or prevent DC/LC from entering the tumor, could be developed as an effective anti-cancer approach.

Statistics

0100200'97'99'01'03'05'07'09'11'13'15'17
Citations per Year

862 Citations

Semantic Scholar estimates that this publication has 862 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Becker1992AnticancerRO, title={Anticancer role of dendritic cells (DC) in human and experimental cancers--a review.}, author={Yechiel Becker}, journal={Anticancer research}, year={1992}, volume={12 2}, pages={511-20} }